Melanoma oncologist at Karolinska University Hospital
Joined May 2021
- Tweets95
- Following118
- Followers148
- Likes490
Hildur Helgadottir retweeted
Welcome to read the Editor´s Choice in May!
➡️ Perioperative immune checkpoint inhibitor therapy across tumors
➡️ Insights and shared lessons from a rapidly evolving field
🔗doi.org/10.1111/joim.70073
👉 Also, read the May issue! onlinelibrary.wiley.com/toc/…
#immunotherapy #oncology
Hildur Helgadottir retweeted
New review to read! Perioperative immune checkpoint inhibitor therapy across tumors.
➡️ Insights and shared lessons from a rapidly evolving field.
➡️ Major evolution in curative-intent oncology.
🔗 doi.org/10.1111/joim.70073
#adjuvanttherapy #immunecheckpointinhibitors #neoplasms
Hildur Helgadottir retweeted
Read more! Immunotherapy used earlier in several cancer types. New article! news.ki.se/immunotherapy-use…
#immunotherapy #oncology
Hildur Helgadottir retweeted
Still no benefit in OS after the introduction of adjuvant immunotherapy for patients with melanoma in Sweden. A nationwide registry-based study published in European Journal of Cancer ejcancer.com/article/S0959-8…
Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study - European Journal of Cancer ejcancer.com/article/S0959-8…
Hildur Helgadottir retweeted
🩺 Real-world #melanoma data suggest flipping nivolumab/ipilimumab doses may lead to longer survival with fewer toxicities compared with standard dosing. #Immunotherapy
👩⚕️ @HildurHelg | @JNCI_Now
Read the article: ascopost.com/news/december-2…
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma academic.oup.com/jnci/articl…
Hildur Helgadottir retweeted
Lower doses of immunotherapy for advanced melanoma demonstrate higher response rates, longer survival, and fewer #SeriousSideEffects compared to traditional dosing, according to recent clinical data. @JNCI_Now doi.org/hbdtx5 medicalxpress.com/news/2025-…
Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends - Girmay - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library onlinelibrary.wiley.com/doi/…
Hildur Helgadottir retweeted
#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available & #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice @TeresaSAmaral #ESMODailyReporter
📌ow.ly/51Cs50TnILV
Hildur Helgadottir retweeted
@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24
Hildur Helgadottir retweeted
Swedish cohort study reveals declining melanoma incidence and mortality in 30-49 year-olds, hinting at potential future population-wide decrease. Increased sun protection awareness may be a contributing factor, but further research is needed. ja.ma/4ggunxt
Hildur Helgadottir retweeted
The risk of skin cancer for adults under the age of 50 is now decreasing for the first time in Sweden, according to a study published in @JAMADerm.
Research by @HildurHelg et al.
news.ki.se/breaking-the-tren…
Does the Germline Genome Encode for the Invasiveness of a Cutaneous Melanoma?
A thought provoking question up for discussion in an Editorial in current JAMA Derm on GWAS article by Ingold et al.
jamanetwork.com/journals/jam…
Such a pleasure to host Professor Michael Atkins here at Karolinska Comprehensive Cancer Center. Excellent presentation and very interesting discussion on burning melanoma topics
Come and work with us in the melanoma research team at Karolinska Comprehensive Cancer Center. We are looking to hire a postdoc researcher in the lab
ki.varbi.com/what:job/jobID:…
